Previous Close | 2.6100 |
Open | 2.5900 |
Bid | 0.0000 x 1000 |
Ask | 0.0000 x 1800 |
Day's Range | 2.5600 - 2.8000 |
52 Week Range | 2.2000 - 14.6300 |
Volume | |
Avg. Volume | 1,879,101 |
Market Cap | 47.893M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.5900 |
Earnings Date | Apr 08, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 15.50 |
WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the closing of its previously-announced $9.4 million private placement with a single institutional investor. “This private placement allows us to continue executing on our aggressive growth plan. Proceeds from the fundraise will primarily be used to fund our commercial strategy including our near-term object
WOBURN, MA., May 16, 2022 (GLOBE NEWSWIRE) -- Biofrontera, Inc. (Nasdaq: BFRI; BFRIW), announced today that it has entered into a securities purchase agreement with a single institutional investor for the purchase of 3,419,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 3,419,000 shares of common stock, in a private placement. The purchase price for one share of common stock (or common stock equivalent) and a warrant to
Conference call begins at 11:00 a.m. Eastern time today WOBURN, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced financial results for the three months ended March 31, 2022, and provided a business update. Financial Highlights & Recent News Total revenues for the first quarter of 2022 were $9.8 million, an increase of 106% from the first quarter of